Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Table 4

Overall survival and disease-specific survival by PSA and therapeutic modality, adapted from Culp et al. (2014) [13].

PSA/therapeutic modality	5-year OS rate (%)	DSS rate (%)
		1 year	3 years	5 years
<20 ng/ml
NLT	33,7	87,3	66,6	57,9
RP	77,1	96,5	89,9	86,7
BT	71,2	95,3	86,5	82,3
≥20 ng/ml
NLT	19,8	81,4	55,6	44,8
RP	55,7	88,8	71,3	63,0
BT	37,3	82,9	58,5	48,1

PSA: prostate-specific antigen; OS: overall survival; DSS: disease-specific survival; RP: radical prostatectomy; BT: brachytherapy; NLT: no local treatment.